BioAge Labs Inc (NASDAQ: BIOA)’s stock price has dropped by -11.78 in relation to previous closing price of 22.67. Nevertheless, the company has seen a loss of -8.80% in its stock price over the last five trading days. globenewswire.com reported 2024-11-07 that Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesity Completed $238.3 million initial public offering and concurrent private placement, cash and cash equivalents sufficient to fund operations and capital expenditures into 2029 Appointed former GSK CEO Jean-Pierre Garnier as Board Chair RICHMOND, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) — BioAge Labs, Inc. (“BioAge”, “the Company”), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging, today provided business updates and reported its third quarter 2024 financial results.
Is It Worth Investing in BioAge Labs Inc (NASDAQ: BIOA) Right Now?
Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 2 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for BIOA is 25.48M, and currently, short sellers hold a 8.66% ratio of that floaft. The average trading volume of BIOA on November 13, 2024 was 500.97K shares.
BIOA’s Market Performance
The volatility ratio for the week is 9.94%, and the volatility levels for the past 30 days are at 8.34% for BioAge Labs Inc The simple moving average for the past 20 days is -13.89% for BIOA’s stock, with a -10.85% simple moving average for the past 200 days.
Analysts’ Opinion of BIOA
Many brokerage firms have already submitted their reports for BIOA stocks, with Morgan Stanley repeating the rating for BIOA by listing it as a “Overweight.” The predicted price for BIOA in the upcoming period, according to Morgan Stanley is $40 based on the research report published on October 21, 2024 of the current year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see BIOA reach a price target of $42. The rating they have provided for BIOA stocks is “Buy” according to the report published on October 21st, 2024.
Citigroup gave a rating of “Buy” to BIOA, setting the target price at $45 in the report published on October 21st of the current year.
BIOA Trading at -10.85% from the 50-Day Moving Average
After a stumble in the market that brought BIOA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -24.87% of loss for the given period.
Volatility was left at 8.34%, however, over the last 30 days, the volatility rate increased by 9.94%, as shares sank -18.37% for the moving average over the last 20 days.
During the last 5 trading sessions, BIOA fell by -8.80%, in comparison to the 20-day moving average, which settled at $23.23. In addition, BioAge Labs Inc saw 9.23% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BIOA starting from Pande Vijay Satyanand, who purchase 126,793 shares at the price of $19.73 back on Oct 01 ’24. After this action, Pande Vijay Satyanand now owns 1,026,793 shares of BioAge Labs Inc, valued at $2,501,626 using the latest closing price.
Pande Vijay Satyanand, the Director of BioAge Labs Inc, purchase 67,096 shares at $19.73 during a trade that took place back on Oct 02 ’24, which means that Pande Vijay Satyanand is holding 1,093,889 shares at $1,323,804 based on the most recent closing price.
Stock Fundamentals for BIOA
The total capital return value is set at -0.19.
Based on BioAge Labs Inc (BIOA), the company’s capital structure generated -0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -2.69. The debt to equity ratio resting at -0.06. The interest coverage ratio of the stock is -16.92.
Currently, EBITDA for the company is -45.81 million with net debt to EBITDA at 6.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 17.63.
Conclusion
In a nutshell, BioAge Labs Inc (BIOA) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
